Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A involved in the pathogenesis of psoriatic disease, has demonstrated sustained long-term efficacy with a favorable safety profile in various psoriatic disease manifestations. However, in real-world settings, secukinumab is prescribed for patients with chronic plaque psoriasis who may have clinical features different than those seen in controlled clinical trials. Therefore, real-world data confirming the efficacy of secukinumab in treating psoriasis becomes essential in the setting of clinical practice where other treatment options are available.
A clinical trial (REALIA) performed in a real-world setting investigated and compared the effectiveness and safety of secukinumab with other biologics and conventional systemic therapies in patients with chronic plaque psoriasis in a real-world setting. 1 The study…
